Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 20/20 | 0.65 |
| ▸ | LPAR3 | Q9UBY5 | 12/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.50 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.50 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16210862 | 1.00 | LPAR1 (0.65) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL15013169 | 0.93 | LPAR1 (0.75) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL15013167 | 0.93 | LPAR1 (0.75) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL14710291 | 0.93 | LPAR1 (0.75) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL14790537 | 0.88 | LPAR1 (0.60) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL14712129 | 0.88 | LPAR1 (0.52) | LPAR1LPAR3HRH1 | |
| SCHEMBL16477192 | 0.87 | LPAR1 (0.67) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL16211009 | 0.86 | LPAR1 (0.51) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL16211008 | 0.86 | LPAR1 (0.51) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL14711412 | 0.86 | LPAR1 (0.86) | LPAR1LPAR3HRH1ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140329871-A1 | SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | LPAR1 1/4885LPAR3 5/4885HRH1 135/4885 |
| US-20140329871-A1 | SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF | MMP1, COL1A1, COL2A1 | LPAR1 709/4885LPAR3 699/4885HRH1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.